Express delivery and free returns within 21 days

Monday, June 27, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

spot_img

Immunology Research and Clinical Care

BD Provides Update on Previously Disclosed Recall of BD Alaris System Hardware

Three of the situations described in this recall, which BD announced on June 30, 2020, have been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. One of the situations was designated as a Class II recall, which means the use of the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

CME America Announces a Follow-Up on the Voluntary Recall of BodyGuard® Infusion System Administration Sets

As part of CME America's commitment to quality, following the previously announced recall (April 27, 2020) of the BodyGuard® Infusion Pump Systems, the company conducted additional flow-rate accuracy testing. This testing revealed that some infusion sets do not meet the ±5% delivery accuracy for the system or the ±13% accuracy identified in the earlier recall notification. Therefore, the use of the pump system potentially could cause over-infusion or under-infusion of therapy and patient harm.

BD Announces BD Kiestra™ ReadA is Now Available to U.S. Clinical Microbiology Laboratories

BD Kiestra™ ReadA provides closed-door incubation and high throughput imaging to streamline workflow, delivering high-quality images for digital interpretation by laboratory staff.

By using this website you agree to accept Medical Device News Magazine Privacy Policy